Middle Molecule Find

Rulebook › V-tags › V242

V242 Bicarbonate distribution: dialysate culture schedule

Written V0242 on the CMS-2567 and in QCOR.

Enforces ANSI/AAMI RD52:2004, adopted by reference at 42 CFR 494.40(a) · Appendix H Rev. 246, page 107 · checked 12 Nov 2026

Cited on this tag? What happens after a citation · One-page sheet for the binder

The regulation

ANSI/AAMI RD52:2004 Requirements as Adopted by Reference 42 CFR 494.40(a)

6.5 Concentrate distribution (Initial Bicarbonate Monitoring)

Once a bicarbonate distribution system has been activated, dialysate should be monitored weekly until sufficient data has been obtained to demonstrate consistent compliance with acceptable levels of contamination. The frequency of monitoring may then be reduced, but monitoring should be performed at least monthly. If elevated bacteria or endotoxin levels are found in the dialysate, all systems involved in dialysate preparation, including the bicarbonate concentrate distribution system should be evaluated and appropriate action, such as disinfection, should be taken. The frequency of monitoring should then be increased until it can be demonstrated that the problem has been resolved.

CMS's interpretive guidance

Interpretive Guidance § 494.40(a)

ANSI/AAMI RD52:2004

6.5 Concentrate distribution

Because acid concentrate distribution systems have been shown not to be subject to bacterial proliferation, it is not necessary to perform bacteria and endotoxin testing on those systems.

Additional Guidance:

Whenever use of a new bicarbonate distribution system is initiated, weekly monitoring of dialysate should occur for at least four consecutive weekly reports of acceptable levels. Evaluation of positive culture or endotoxin reports should also consider the number of positives in relationship to the number of samples taken. For example, if one sample out of 10 has a count of 53, while the other 9 have no growth, repeating the culture of one or more sites may be the first action taken. The medical director should be involved in any decisions for determining the appropriate action(s) to address abnormal culture or endotoxin results, i.e., growth exceeds permissible standards.

Verbatim from Appendix H Rev. 246, with CMS's headings, lists and bold. Check page 107 (the full 469-page PDF) before quoting it.